Jemperli a Key Oncology Drug for GSK In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States.

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

In December 2024, GSK reported that the Phase III FIRST-ENGOT-OV44 trial of Zejula and Jemperli met its primary endpoint of progression-free survival in treating first-line advanced ovarian cancer.

In comparison, I expect it to be $1.05, which is above the midpoint of the above range due to stronger sales of Cabenuva, Jemperli, Ojjaara/Omjjara, and Dovato. Was Emma Walmsley, CEO of GSK ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by new patient starts across all regions. New blood cancer drug Ojjaara/Omjjara generated ...

Jemperli added £149 million to GSK’s top line compared with £130 million in third-quarter 2024, driven by increased patient uptake in the United States following approval for a broader patient ...

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced ...

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...